INDP · TickerCove

INDPIndaptus Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-25

Horizon

Issued 2026-09-25 at $3.85 · now $3.85 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, INDP has typically landed between $2.36 and $5.96 — a range of −38.7% to +54.8% from the issuance price $3.85.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

2,779 overlapping 1 month windows · 2015-08-04 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($3.85) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$3.85 · 82% of range

$0.9361 low$4.5 high

Trailing 52 weeks to 2026-09-25 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,391 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.7%

90% CI 51.5%–55.9%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−9.1%

typical move · IQR 26.1%

−38.7%worst (p90)+54.8%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where INDP has typically landed a month from the 2026-09-25 close of $3.85 — the range is history, not a prediction.

now $3.85 (+0.0%)
typical $3.5 (-9.1%)
middle 50% $3–$4
90% range $2.36–$5.96

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,779 windows spanning 2015-08-04 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2019-06-27	−89.4%	−89.4%	+1.9%
2019-07-11	−89.1%	−89.1%	+0.0%
2019-06-28	−89.0%	−89.6%	+0.0%
3 best
2026-08-18	+319.8%	+0.0%	+319.8%
2026-08-19	+277.7%	+0.0%	+318.1%
2026-08-25	+263.6%	+0.0%	+263.6%

2,779 overlapping windows · 2015-08-04 – 2026-09-25 · not cherry-picked

Pending catalysts

2027-06-30 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

45%

−3.7%

n=11

Feb

36%

−0.1%

n=11

Mar

45%

−6.3%

n=11

Apr

36%

+2.1%

n=11

May

36%

−8.5%

n=11

Jun

55%

+6.3%

n=11

Jul

36%

−11.3%

n=11

Aug

36%

+2.4%

n=11

Sep

42%

+14.5%

n=12

Oct

27%

−9.1%

n=11

Nov

27%

−5.7%

n=11

Dec

45%

−2.7%

n=11

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-03-23	Lazar David E.	director	Sale	196,800	—	−65.6% of holding	+90.3%	+100.5%	103,200	Form 4 · filed 1 day after the trade
2026-03-23	Lazar David E.	director	Sale	700,000	—	−100.0% of holding	+90.3%	+100.5%	0	Form 4 · filed 1 day after the trade
2026-03-23	Lazar David E.	director	Sale	196,800	—	−65.6% of holding	+90.3%	+100.5%	103,200	Form 4 · filed 1 day after the trade
2026-03-23	Lazar David E.	director	Sale	700,000	—	−100.0% of holding	+90.3%	+100.5%	0	Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

68 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-02-26	Jabbour Jerome D	director	Award / grant	25,000	25,000	Form 4
2026-02-11	Meckler Jeffrey A	director	Disposition	12,136	0	Form 4
2026-02-11	Meckler Jeffrey A	director	Award / grant	12,136	12,136	Form 4
2026-02-11	Meckler Jeffrey A	director	Award / grant	3,033	3,033	Form 4
2026-02-11	Meckler Jeffrey A	director	Disposition	3,033	0	Form 4
2026-02-11	Meckler Jeffrey A	director	Disposition	1,519	0	Form 4
2026-02-11	Meckler Jeffrey A	director	Award / grant	1,519	1,519	Form 4
2026-02-11	Meckler Jeffrey A	director	Disposition	12,136	0	Form 4
2026-02-11	Meckler Jeffrey A	director	Award / grant	12,136	12,136	Form 4
2026-02-11	Meckler Jeffrey A	director	Disposition	3,033	0	Form 4
2026-02-11	Meckler Jeffrey A	director	Award / grant	3,033	3,033	Form 4
2026-02-11	Meckler Jeffrey A	director	Disposition	1,519	0	Form 4
2026-02-11	Meckler Jeffrey A	director	Award / grant	1,519	1,519	Form 4
2026-01-20	Ben-Tzvi Avraham	director	Award / grant	25,000	25,100	Form 4
2026-01-07	NATAN DAVID	director	Award / grant	25,000	25,000	Form 4
2025-12-23	Ben-Tzvi Avraham	director	Award / grant	25,000	25,000	Form 4
2025-12-22	Meckler Jeffrey A	director	Award / grant	216,617	229,929	Form 4
2025-12-22	Linscott Walt Addison	officer	Award / grant	54,421	54,426	Form 4
2025-12-22	Newman Michael James	director	Award / grant	52,204	101,074	Form 4
2025-12-22	Sassi Nir	officer	Award / grant	26,758	26,758	Form 4
2025-07-27	Meckler Jeffrey A	director	Award / grant	12,136	16,688	Form 4
2025-07-27	Meckler Jeffrey A	director	Award / grant	6,068	13,312	Form 4
2025-06-10	Hayes William B	director	Award / grant	12,500	12,500	Form 4
2025-06-10	Karah Hila	director	Award / grant	12,500	12,500	Form 4
2025-06-10	MADDALUNA ANTHONY J	director	Award / grant	12,500	12,500	Form 4
2025-06-10	Martell Robert	director	Award / grant	12,500	12,500	Form 4
2025-06-10	Gilbert Mark John	director	Award / grant	12,500	12,500	Form 4
2025-06-10	Pomerantz Roger	director	Award / grant	30,000	30,000	Form 4
2025-04-10	Pomerantz Roger	director	Disposition	500	0	Form 4
2025-04-10	Hayes William B	director	Disposition	500	0	Form 4
2025-04-10	MADDALUNA ANTHONY J	director	Disposition	500	0	Form 4
2025-04-10	Karah Hila	director	Disposition	500	0	Form 4
2025-04-10	Sassi Nir	officer	Disposition	2,500	0	Form 4
2025-04-10	Meckler Jeffrey A	director	Disposition	4,750	0	Form 4
2025-04-10	Linscott Walt Addison	officer	Disposition	2,500	0	Form 4
2025-04-10	Meckler Jeffrey A	director	Disposition	3,750	0	Form 4
2025-04-10	Pomerantz Roger	director	Disposition	250	0	Form 4
2025-04-10	Hayes William B	director	Disposition	250	0	Form 4
2025-04-10	MADDALUNA ANTHONY J	director	Disposition	250	0	Form 4
2025-04-10	Karah Hila	director	Disposition	281	0	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

27d remaining

2026-09-2610% elapsed2026-10-26

Logged immutably 2026-09-26; scored automatically on 2026-10-26 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Pending catalysts

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i